Locations:
Search
Experience to date highlights need for immunotherapy focus
Rationale and status reports on mechanistically diverse strategies
No evidence of residual tumor or recurrence at 6.5 years of follow-up
Individual tumor DNA may be key
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Established lymphoma/leukemia therapy also targets glioma stem cells
Hyperthermia augments radiation therapy
Hypoxic induction of vasorin regulates Notch1 turnover
First new medical intervention in a decade to demonstrate improved survival
Glioblastoma CSCs express less TLR4
Finding has potential to improve treatment
Advertisement
Advertisement